Table 1. Haematological assessment after the administration of EGFR(2R)-lytic hybrid peptide to mice.

	EGFR(2R)-lytic	Lytic	PBS	P
WBC (×103/μL)	2.5 ± 0.7	2.5 ± 0.2	3.1 ± 1.0	0.341
RBC (×104/μL)	1002.2 ± 62.1	909.4 ± 138.4	907.8 ± 216.3	0.550
Hb (g/dL)	16.1 ± 0.1	15.8 ± 0.7	15.3 ± 2.1	0.593
Hct (%)	52.9 ± 3.3	49.1 ± 7.4	47.6 ± 10.5	0.549
Plt (×104/μL)	81.5 ± 4.6	77.0 ± 11.6	69.8 ± 26.0	0.546

EGFR(2R)-lytic hybrid peptide (4 mg/kg) was intravenously injected into BALB/c mice twice a week for a total of six doses. Blood samples were obtained one day after the final intravenous injection of EGFR(2R)-lytic hybrid peptide. P-values were assessed by analysis of variance (ANOVA). Data are presented as the mean ± S.D. (n = 5). Note that EGFR(2R)-lytic hybrid peptide administration did not cause any haematological abnormalities in mice.